搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
17 分钟
Illegally repackaged drugs for arthritis treatment seized from Ghaziabad’s Modinagar
Officials said Bhatia allegedly procured tablets of phenylbutazone, piroxicam and dexamethasone from several suppliers in ...
2 天
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
腾讯网
1 天
葛兰素史克(GSK.US)药物在多发性骨髓瘤研究中将死亡风险降低 42%
智通财经APP获悉,葛兰素史克(GSK.US)报告称,一项研究表明,其药物 belantamab mafodotin 能够将多发性骨髓瘤患者在首次复发时或复发后的死亡风险降低 42%。该研究正在评估 belantamab mafodotin 与 ...
Daily
18 小时
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma ...
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
2 天
GSK says median overall survival not reached in multiple myeloma study
GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...
2 天
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...
TipRanks on MSN
3 天
C4 Therapeutics presents cemsidomide Phase 1 data at ASH
C4 Therapeutics (CCCC) presented clinical data from the ongoing Phase 1 trial of cemsidomide, an orally bioavailable small ...
2 天
on MSN
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...
1 天
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
2 天
J&J : CARVYKTI Shows Higher MRD Negativity Rates Vs. Standard Therapies In Phase 3 Study
Johnson & Johnson (JNJ) announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI ...
Joplin Globe
2 天
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death ...
The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...
11 小时
Rs 12 lakh meds repackaged and sold as pain relievers seized from 2 godowns in Modinagar
Authorities seize Rs 12 lakh worth of repackaged medications being illegally sold as pain relievers in Modinagar. Drug inspector highlights severe health risks and violations of the Drugs and ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈